ArticleBulletin of the World Health Organization2016
Essential medicines for cancer: WHO recommendations and national priorities.
Article in Bulletin of the World Health Organization, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature.Frontiers in public health · 2021Pooled it
- Identifying Breast Cancer Care Quality Measures for a Cancer Facility in Rural Sub-Saharan Africa: Results of a Systematic Literature Review and Modified Delphi Process.JCO global oncology · 2020Pooled it
- Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.CPT: pharmacometrics & systems pharmacology · 2024Trial
- Article
- FOXM1 induces therapy resistance and inhibits apoptosis in a variety of human cancers.Cell death & disease · 2026Review
- Metronomic chemotherapy in resource-limited settings: evidence, opportunities, and future directions.Medical oncology (Northwood, London, England) · 2026Review
- Treatment Patterns and Outcomes of Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Tanzania.JCO global oncology · 2025Article
- Quality indicators and patient outcome measures for palliative care in cancer patients: a systematic review.Ecancermedicalscience · 2025Review
- Factors associated with COVID-19 vaccine acceptance among medical laboratory workers in South Africa.Journal of public health in Africa · 2025Article
- Disparities in availability of new cancer drugs worldwide: 1990-2022.BMJ global health · 2024Article
- Article
- Chlorin Conjugates in Photodynamic Chemotherapy for Triple-Negative Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Essential cancer medicines and cancer outcomes: Cross-sectional study of 124 countries.Cancer medicine · 2023Article
- Application of a Novel Aptamer Beacon for Rapid Detection of IgG1 Antibody Drugs.Applied biochemistry and biotechnology · 2023Article
- Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015-2021.BMJ global health · 2023Article
- Review
- Quality measures for palliative care in patients living with cancer in low- and middle-income countries: a scoping review protocol.Systematic reviews · 2023Article
- Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011-2021.EClinicalMedicine · 2023Article
- Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment?World journal of gastrointestinal oncology · 2023Review
- Endemic Kaposi's Sarcoma.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo examine, for essential anti-cancer medicines, the alignment of national lists of essential medicines and national reimbursable medicines lists with the World Health Organization's (WHO's) Model Lists.
methodsNational medicine lists for 135 countries with per-capita gross national incomes below 25 000 United States dollars in 2015 were compared with WHO's 2013 and 2015 Model Lists of Essential Medicines. Correlations between numbers of anti-cancer medicines included in national lists and gross national income (GNI), government health expenditure and number of physicians per 1000 population were evaluated.
findingsOf the 25 anti-cancer medicines on the 2013 Model List and the 16 added via the 2015 revision of the Model List, 0-25 (median: 17) and 0-15 (median: 3) appeared in national lists, respectively. There was considerable variability in these numbers within and between World Bank income groups. Of the 16 new medicines included in the 2015 Model List, for example, 0-10 (median: 1) and 2-15 (median: 10) were included in the national lists of low-income and high-income countries, respectively. The numbers of these new medicines included in national lists were significantly correlated (
conclusionSubstantial numbers of anti-cancer medicines are included in national lists of low- and middle-income countries but the availability, affordability, accessibility and administration feasibility of these medicines, at country-level, need assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.